Hepatitis C viral kinetics: the past, present, and future
Hepatitis C virus (HCV) is a positive-strand RNA virus of the Flaviviridae family that primarily
infects hepatocytes and can lead to liver cirrhosis, hepatocellular carcinoma, liver failure …
infects hepatocytes and can lead to liver cirrhosis, hepatocellular carcinoma, liver failure …
Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness
KC Sumino, MJ Walter, CL Mikols, SA Thompson… - Thorax, 2010 - thorax.bmj.com
Background A specific diagnosis of a lower respiratory viral infection is often difficult despite
frequent clinical suspicion. This low diagnostic yield may be improved by use of sensitive …
frequent clinical suspicion. This low diagnostic yield may be improved by use of sensitive …
Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity
DA Sheridan, SH Bridge, DJ Felmlee, MME Crossey… - Journal of …, 2012 - Elsevier
BACKGROUND & AIMS: Hepatitis C virus (HCV) interacts with apolipoproteins B (apoB) and
E (apoE) to form infectious lipoviral particles (LVP). Response to peginterferon is influenced …
E (apoE) to form infectious lipoviral particles (LVP). Response to peginterferon is influenced …
Future hepatitis C virus treatment: interferon‐sparing combinations
E Gane - Liver International, 2011 - Wiley Online Library
An estimated million people have chronic hepatitis C virus (HCV) infection. With current
treatment success rates, by 2030, more than 40% will be cirrhotic and the number of cases …
treatment success rates, by 2030, more than 40% will be cirrhotic and the number of cases …
The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?
JJ Feld - Antiviral research, 2014 - Elsevier
Interferon has been the backbone of therapy for hepatitis C virus (HCV) infection for over 20
years. Initial response rates were poor, however they have slowly but steadily improved …
years. Initial response rates were poor, however they have slowly but steadily improved …
Immunological predictors of nonresponse to directly acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
K Childs, E Merritt, A Considine… - Open forum …, 2017 - academic.oup.com
Background Sustained virological response rates (SVRs) to directly acting antiviral (DAA)
therapy for hepatitis C virus (HCV) are lower in decompensated cirrhosis. Markers of innate …
therapy for hepatitis C virus (HCV) are lower in decompensated cirrhosis. Markers of innate …
The natural killer cell response to HCV infection
G Ahlenstiel - Immune Network, 2013 - synapse.koreamed.org
In the last few years major progress has been made in better understanding the role of
natural killer (NK) cells in hepatitis C virus (HCV) infection. This includes multiple pathways …
natural killer (NK) cells in hepatitis C virus (HCV) infection. This includes multiple pathways …
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 …
MW Taylor, T Tsukahara, JN McClintick… - Journal of translational …, 2008 - Springer
Abstract Background and Aims This study determined the kinetics of gene expression during
the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntron™) and ribavirin …
the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntron™) and ribavirin …
Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1
ES Andersen, M Ruhwald, B Moessner… - European journal of …, 2011 - Springer
Abstract Information about the stage of liver fibrosis is important for managing patients with
chronic hepatitis C (CHC). The aim of this study was to evaluate 12 plasma markers for …
chronic hepatitis C (CHC). The aim of this study was to evaluate 12 plasma markers for …
CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients
Egypt has the highest prevalence of hepatitis C virus infection worldwide. CXCL10 is a
potent chemoattractant that directs effector lymphocytes to sites of inflammation. It has been …
potent chemoattractant that directs effector lymphocytes to sites of inflammation. It has been …